These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2793374)

  • 1. Phase I study of 4'-deoxydoxorubicin (esorubicin) in children with malignant solid tumors.
    Pratt CB; Douglass EC; Meyer WH; Hayes FA; Horowitz ME; Thompson EI; Avery L
    Invest New Drugs; 1989 Jul; 7(2-3):209-11. PubMed ID: 2793374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of 4'-deoxydoxorubicin given weekly.
    Sessa C; Bosia L; Kaplan S; Pusterla C; Varini M; Cavalli F
    Invest New Drugs; 1984; 2(4):369-73. PubMed ID: 6511241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial with 4'-deoxydoxorubicin (esorubicin).
    Rozencweig M; Crespeigne N; Kenis Y
    Invest New Drugs; 1983; 1(4):309-13. PubMed ID: 6678877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    McGuire WP; Blessing JA; Yordan E; Beecham J
    Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study with 4'-deoxydoxorubicin.
    Ferrari L; Rossi A; Brambilla C; Bonfante V; Villani F; Crippa F; Bonadonna G
    Invest New Drugs; 1984; 2(3):287-95. PubMed ID: 6511235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
    McGuire WP; Blessing JA; Berman ML
    Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of 4'-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer.
    Braich T; Ahmann FR; Garewal HS; Robertone A; Salmon SE
    Invest New Drugs; 1986; 4(2):193-6. PubMed ID: 3733379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
    Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
    Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study.
    Pratt CB; Vietti TJ; Etcubanas E; Sexauer C; Krance RA; Mahoney DH; Patterson RB
    Invest New Drugs; 1986; 4(1):43-8. PubMed ID: 3700039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
    Muss HB; Van Echo D; Korzun AH; Henderson IC; Campbell T; Vogelzang NJ; Rice MA; Wood W
    Am J Clin Oncol; 1990 Jun; 13(3):233-7. PubMed ID: 2346128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
    Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
    Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
    Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).
    Hochster H; Hunt M; Green M; Parkinson D; Smith T
    Invest New Drugs; 1990 Aug; 8(3):329-32. PubMed ID: 2272773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of carboplatin (CBDCA) in children with cancer.
    Bacha DM; Caparros-Sison B; Allen JA; Walker R; Tan CT
    Cancer Treat Rep; 1986 Jul; 70(7):865-9. PubMed ID: 3521846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
    Frustaci S; Gasparini G; Veronesi A; Tirelli U; Pacciarini MA; Crivellari D; Zagonel V; Monfardini S
    Invest New Drugs; 1987; 5(3):307-9. PubMed ID: 3667167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
    Rigas JR; Kris MG; Gralla RJ; Heelan RT; Marks LD
    Invest New Drugs; 1991 May; 9(2):187-90. PubMed ID: 1651908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
    Vaughn CB; Salmon SE; Fleming TR
    Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of esorubicin (4'deoxydoxorubicin).
    Garewal HS; Robertone A; Salmon SE; Jones SE; Alberts DS; Brooks R
    J Clin Oncol; 1984 Sep; 2(9):1034-9. PubMed ID: 6470753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.